Science Matters: CD47 Pathway Links To CV Disease, New Drug Development Opportunities
Executive Summary
Initial research about inhibiting CD47 signaling on tumor cells has meant a focus on oncology drug development. New research shows that inhibiting this cell surface molecule could be used to treat atherosclerosis.
You may also be interested in...
Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition
Emerging Company Profile: Toronto biotech thinks it will differentiate from the current IO paradigm with CD47 inhibition, and from competitors in its space by directly targeting a receptor found in the tumor microenvironment.
Forty Seven Raises $75 Million For Possible 'Universal' Cancer Therapy
Forty Seven Inc. spun out of Stanford with a $75 million Series A and an immuno-oncology development program that's already in the clinic with data expected later this year.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.